Page last updated: 2024-12-10

15-deoxy-delta(12,14)-prostaglandin j2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 15-deoxy-Δ(12,14)-prostaglandin J2 (15d-PGJ2)

**15d-PGJ2** is a prostaglandin J2 (PGJ2) derivative with several key features:

* **Structure:** It lacks the hydroxyl group at position 15 and has a double bond between carbons 12 and 14.
* **Biological Activity:** It's a potent anti-inflammatory and anti-proliferative molecule with various biological effects, including:
* **Inhibition of NF-κB:** 15d-PGJ2 blocks the activity of Nuclear Factor kappa B (NF-κB), a key transcription factor involved in inflammation and immune responses.
* **Induction of apoptosis:** It can induce programmed cell death in cancer cells.
* **Regulation of lipid metabolism:** It plays a role in regulating lipid metabolism and insulin sensitivity.

**Why 15d-PGJ2 is important for research:**

* **Therapeutic potential:** Its potent anti-inflammatory and anti-proliferative properties make it a potential therapeutic target for various diseases, including:
* **Cancer:** 15d-PGJ2 is being investigated for its potential anti-cancer effects, particularly in colon, breast, and prostate cancer.
* **Inflammatory diseases:** It shows promise in treating inflammatory bowel disease, rheumatoid arthritis, and asthma.
* **Metabolic disorders:** 15d-PGJ2 is being explored for its potential benefits in treating type 2 diabetes and obesity.
* **Understanding cellular mechanisms:** Studying 15d-PGJ2's biological activity provides insights into the mechanisms of inflammation, apoptosis, and lipid metabolism.
* **Drug development:** 15d-PGJ2 has inspired the development of synthetic analogs with improved pharmacological properties, aiming to optimize its therapeutic potential.

**Challenges in research:**

* **Limited stability:** 15d-PGJ2 is a highly reactive molecule with limited stability, making it challenging to work with.
* **Off-target effects:** 15d-PGJ2 has diverse biological effects, and its off-target effects need to be investigated to ensure its safe and effective use.

**Overall, 15d-PGJ2 remains a promising molecule with vast potential for therapeutic applications. Continued research is essential to fully understand its mechanisms of action and develop safe and effective therapies based on this molecule.**

15-deoxy-delta(12,14)-prostaglandin J2: 15-deoxy-PGJ2 is also available; check for double bonds (indicated by delta) at 12 and 14 positions [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

15-deoxy-Delta(12,14)-prostaglandin J2 : A prostaglandin J derivative comprising prostaglandin J2 lacking the 15-hydroxy group and having C=C double bonds at the 12- and 14-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5311211
CHEMBL ID482477
CHEBI ID34159
SCHEMBL ID3177249
MeSH IDM0255641

Synonyms (84)

Synonym
(5z,12e,14e)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
15-deoxy-delta(12,14)-prostaglandin j2
delta-12,14-15-deoxy-pgj2
CHEBI:34159 ,
BRD-K05396879-001-02-6
(z)-7-[(1s,5e)-5-[(e)-oct-2-enylidene]-4-oxo-1-cyclopent-2-enyl]hept-5-enoic acid
gtpl2692
15-deoxy-delta(12,14)-pgj2
IDI1_033831
15-deoxy-pgj2
LMFA03010021
15-deoxy-delta-12,14-prostaglandin j2
15-deoxy-delta-12,14-pgj2
11-oxo-5z,9,12e,14e-prostatetraenoic acid
BSPBIO_001361
SPECTRUM5_001971
15-deoxy-delta12,14-prostaglandin
prosta-5,9,12,14-tetraen-1-oic acid, 11-oxo-, (5z,12e,14e)-
15-deoxy-delta 12, 14-prostaglandin j2
15-deoxy-delta12,14-pgj2
87893-55-8
delta12,14-pgj 2
prosta-5,9,12,14-tetraen-1-oic acid, 11-oxo-, (5z,12e,14e)- (9ci)
15-deoxy-delta12,14-prostaglandin j2
15-deoxy .delta.12,14pgj2
prosta-5,9,12,14-tetraen-1-oic acid, 11-oxo (5z,12e,14e)
(z)-7-[(1s,5e)-5-[(e)-oct-2-enylidene]-4-oxo-cyclopent-2-en-1-yl]hept-5-enoic acid
87-57-0
15-deoxy-delta-12, 14 pgj-2
NCGC00161304-02
15d-pgj2
NCGC00161304-01
NCGC00161304-04
NCGC00161304-03
NCGC00161304-05
15-deoxy-d-12,14-pgj2
HMS1989E03
BML2-B05
HMS1791E03
HMS1361E03
15-deoxy-d12,14-prostaglandin j2
bdbm50270612
7-((s)-5-(oct-2-enylidene)-4-oxocyclopent-2-enyl)hept-5-enoic acid
CHEMBL482477 ,
(z)-7-[(1s,5e)-5-[(e)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
prosta-5,9,12,14-tetraen-1-oicacid, 11-oxo-, (5z,12e,14e)-
SCHEMBL3177249
DTXSID1043706
15-deoxy-?-12,14-prostaglandin j2
(5z,12e,14e)-11-oxo-prosta-5,9,12,14-tetraen-1-oic acid
15-deoxy-| currency-12,14-prostaglandin j2
ALI977775J ,
15 pgj2
15-deoxy-.delta.12,14-prostaglandin j2
.delta.12,14-pgj 2
j694.826j
15-dpgj2
AKOS024457040
HMS3648L20
HMS3648L22
HMS3402E03
unii-ali977775j
J-002852
15-deoxy-?12,14-prostaglandin a2
15-deoxy-delta12,14-prostaglandin j2, >=95% (hplc), 1 mg/ml in methyl acetate
11-oxo-5z,9,12,14-prostatetraenoate
(5z,12e,14e) 11-oxo prosta-5,9,12,14-tetraen-1-oic acid
15-deoxy-prostaglandin j2
(5z,12e,14e) 11-oxo prosta-5,9,12,14-tetraen-1-oate
(5z,12e,14e)-11-oxo-prosta-5,9,12,14-tetraen-1-oate
11-oxo-5z,9,12,14-prostatetraenoic acid
delta12,14-pgj2
15d-prostaglandin j2
HY-108568
Q27070775
sr-05000002103
SR-05000002103-3
SR-05000002103-2
CS-0029180
15-deoxy- delta 12,14-prostaglandin j2 solution
11-oxo-prosta-5z,9,12e,14e-tetraen-1-oic acid
15-deoxy- delta 12,14-prostaglandin a2
PD020570
15-deoxy- delta 12,14-prostaglandin j2

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of HIV protease inhibitors is altered by P-glycoproteins (P-gp)."( High sodium butyrate levels induce MDR1 activation in colorectal cells: Impact of 15-deoxy-Δ(12,14)-prostaglandin J(2) on the resistance to saquinavir.
Dumais, N; Pasvanis, S; Tremblay, S, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
electrophilic reagentA reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.
insulin-sensitizing drugAn agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins J
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (51)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Eicosanoid metabolism via cyclooxygenases (COX)137
Prostaglandin and leukotriene metabolism in senescence619
Arachidonic acid (AA, ARA) oxylipin metabolism076
Eicosanoid lipid synthesis map17
Eicosanoid synthesis026
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency24.80330.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency28.79680.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency20.15900.125919.1169125.8920AID2549; AID504841
Chain A, CruzipainTrypanosoma cruziPotency35.48130.002014.677939.8107AID1476
phosphopantetheinyl transferaseBacillus subtilisPotency67.83350.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency26.80880.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency2.99350.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency21.16990.035520.977089.1251AID504332
prostaglandin E2 receptor EP2 subtypeHomo sapiens (human)Potency41.76290.14825.531235.2093AID743167
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency15.53460.354828.065989.1251AID504847
DNA polymerase kappa isoform 1Homo sapiens (human)Potency7.19120.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency15.84890.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)5.60000.00033.166210.0000AID482142
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)Kd2.00000.00120.95314.9800AID677050
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (90)

Processvia Protein(s)Taxonomy
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID348777Inhibition of iNOS expression in LPS/IFN-gamma-stimulated mouse RAW264.7 cells at 10 uM2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Analogues of 2-phenyl-ethenesulfonic acid phenyl ester have dual functions of inhibiting expression of inducible nitric oxide synthase and activating peroxisome proliferator-activated receptor gamma.
AID1070424Activation of Nrf2 (unknown origin) expressed in CHO-ARE-Luc cells after 18 hrs by luciferase reporter gene assay2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Identification of chromomoric acid C-I as an Nrf2 activator in Chromolaena odorata.
AID405533Inhibition of mPGES12008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID468335Binding affinity to PPARgamma in C57BL/6J mouse macrophages assessed as increase in Cpt1alpha mRNA level at 5 uM after 48 hrs by real-time PCR analysis2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins.
AID1469816Ratio of Kinact to Ki for recombinant human GSTP1-12017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.
AID677050Binding affinity to PPARgamma2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.
AID348772Suppression of LPS/IFN-gamma-stimulated NO production in mouse RAW264.7 cells2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Analogues of 2-phenyl-ethenesulfonic acid phenyl ester have dual functions of inhibiting expression of inducible nitric oxide synthase and activating peroxisome proliferator-activated receptor gamma.
AID482142Activation of TRPA1 channel2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID468334Binding affinity to PPARgamma in C57BL/6J mouse macrophages assessed as increase in CD36 mRNA level at 5 uM after 48 hrs by real-time PCR analysis2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins.
AID348778Inhibition of iNOS expression in LPS/IFN-gamma-stimulated mouse RAW264.7 cells at 5 uM2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Analogues of 2-phenyl-ethenesulfonic acid phenyl ester have dual functions of inhibiting expression of inducible nitric oxide synthase and activating peroxisome proliferator-activated receptor gamma.
AID405528Inhibition of mPGES1 at 10 uM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID430850Inhibition of human FLAG-tagged IKK-beta expressed in HEK293 cells at 50 uM by Western blot analysis in presence of ATP2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Peperomins as anti-inflammatory agents that inhibit the NF-kappaB signaling pathway.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)2005Biochemical and biophysical research communications, Nov-18, Volume: 337, Issue:2
Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)1995Cell, Dec-01, Volume: 83, Issue:5
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)1998Analytical biochemistry, Mar-15, Volume: 257, Issue:2
Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)1997Proceedings of the National Academy of Sciences of the United States of America, Apr-29, Volume: 94, Issue:9
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)2002Cellular signalling, Jul, Volume: 14, Issue:7
Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (559)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's35 (6.26)18.2507
2000's408 (72.99)29.6817
2010's108 (19.32)24.3611
2020's8 (1.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.77 (24.57)
Research Supply Index6.34 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (13.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.18%)5.53%
Reviews18 (3.19%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other545 (96.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]